T3D Therapeutics' Unattributed - III Round

T3D Therapeutics raised a round of funding on March 12, 2018.

T3D Therapeutics is a privately-held pharmaceutical R&D company developing and commercializing T3D-959, potentially an optimal disease remedial therapeutic for the treatment of Alzheimer's Disease. Un…

Articles about T3D Therapeutics' Unattributed - III Round: